Education
About Us
Working with TipRanks
Follow Us
C-Rad AB Class B (DE:24C)
FRANKFURT:24C
24C Stock Chart & Stats
€2.83
€0.01(0.40%)
At close: 4:00 PM EST
€2.83
€0.01(0.40%)
Day’s Range― - ―
52-Week Range€2.22 - €3.31
Previous CloseN/A
Volume0.00
Average Volume (3M)162.00
Market Cap
€79.55M
Enterprise Value€698.74M
Total Cash (Recent Filing)€171.20M
Total Debt (Recent Filing)€18.80M
Price to Earnings (P/E)168.7
Beta0.29
Next Earnings
May 06, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding32,904,050
10 Day Avg. Volume200
30 Day Avg. Volume162
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)3.12
Price to Sales (P/S)2.45
P/FCF Ratio15.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.24
Revenue Forecast (FY)€47.93M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetDebt-to-equity has remained minimal (roughly ~0.6%–5.4% 2023–2025) while equity grew materially (~200m to ~347m). That conservative capital structure provides durable financial flexibility to fund R&D, service expansion and absorb demand shocks without needing frequent external financing.
Structurally High Gross MarginsSustained gross margins in the mid-to-high 60s reflect product differentiation and software/recurring revenue mix. High gross profitability supports long-term margin sustainability, funds service and software development, and creates room to invest in go-to-market or integration partnerships without immediate margin erosion.
Improved Cash Generation In 2025Material operating and free cash flow (~71m) in 2025 enhances self funding for maintenance, upgrades and recurring-service investments. Strong FCF in the most recent year strengthens long-term ability to support installed-base monetization and reduces reliance on external capital for strategic initiatives.
Bears Say
Profitability Reset In 2025A sharp net margin collapse from ~12% to ~2.4% signals structural pressure on operating profitability—whether from mix, pricing, or cost rises. Persistently lower margins would constrain reinvestment, reduce returns on capital, and could force strategic choices that slow long-term growth or product roadmap spending.
Negative Revenue & EPS GrowthDeclining top-line and steep EPS contraction indicate weakening demand or execution challenges. Continued negative growth undermines operating leverage and the conversion of installed base to recurring revenue, making it harder to sustain R&D, service expansion, and long-term margin recovery without corrective strategy.
Uneven Historical Cash FlowHistorical FCF volatility—including a negative year in 2022—raises uncertainty about cash generation consistency. Volatile cash flow complicates budgeting for product development, service scale-up and may necessitate external financing in downturns despite recent improvement, increasing execution risk over time.
C-Rad AB Class B News
24C FAQ
What was C-Rad AB Class B’s price range in the past 12 months?
C-Rad AB Class B lowest stock price was €2.21 and its highest was €3.31 in the past 12 months.
What is C-Rad AB Class B’s market cap?
C-Rad AB Class B’s market cap is €79.55M.
When is C-Rad AB Class B’s upcoming earnings report date?
C-Rad AB Class B’s upcoming earnings report date is May 06, 2026 which is in 62 days.
How were C-Rad AB Class B’s earnings last quarter?
C-Rad AB Class B released its earnings results on Feb 12, 2026. The company reported €0.019 earnings per share for the quarter, missing the consensus estimate of €0.063 by -€0.044.
Is C-Rad AB Class B overvalued?
According to Wall Street analysts C-Rad AB Class B’s price is currently Overvalued.
Does C-Rad AB Class B pay dividends?
C-Rad AB Class B does not currently pay dividends.
What is C-Rad AB Class B’s EPS estimate?
C-Rad AB Class B’s EPS estimate is 0.04.
How many shares outstanding does C-Rad AB Class B have?
C-Rad AB Class B has 32,904,050 shares outstanding.
What happened to C-Rad AB Class B’s price movement after its last earnings report?
C-Rad AB Class B reported an EPS of €0.019 in its last earnings report, missing expectations of €0.063. Following the earnings report the stock price went down -1.718%.
Which hedge fund is a major shareholder of C-Rad AB Class B?
Currently, no hedge funds are holding shares in DE:24C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
C-Rad AB Class B
C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery. The company's products also comprise Catalyst Tomo, an enhanced positioning solution for tomotherapy; Catalyst PT, a real-time tracking solution for particle therapy; Cyrpa laser positioning products; cAccessory, which automates the registration and validation of treatment accessories; and cPatient that automates patient identity validation without the need for contact between patients and devices. In addition, it offers installation, application training, and aftersales services. C-Rad AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
Technical Analysis
Paxman AB
―
Senzime AB
―
Bactiguard Holding AB
―
Integrum AB Class B
―
Sedana Medical AB
―